Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28334116 | 0.98 | CES2 (0.44) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL30697596 | 0.85 | MEN1 (0.38) | CYP1A2CYP3A4MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL29289841 | 0.83 | MAPT (0.43) | CES2CES1IDO1TDO2NPC1 | |
| SCHEMBL20365473 | 0.82 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21401494 | 0.82 | PSEN1 (0.40) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL18358093 | 0.81 | ALOX15 (0.40) | NPC1RAB9ASMN1; SMN2POLBLMNA | |
| SCHEMBL18358263 | 0.81 | PDE2A (0.53) | IDO1GAACYP1A2CYP2C19 | |
| SCHEMBL31560789 | 0.81 | CES2 (0.46) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL8595608 | 0.81 | CES2 (0.58) | CES2CES1PSEN1PSEN2APH1B | |
| SCHEMBL6400373 | 0.81 | CES2 (0.58) | CES2CES1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085429-B | Aromatic heterocyclic derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2019-12-10 | — | — | CN | disclosed |
| CN-104781256-B | 3,4 pairs of substitution oxazolidinone derivatives and its purposes as the inhibitor of calcium-activated potassium channel | 霍夫曼-拉罗奇有限公司 | 2017-09-29 | — | — | CN | disclosed |
| EP-2912034-B1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-9611232-B2 | Oxazolidinone and imidazolidinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| CN-105085429-A | Heteroaromatic derivative and application thereof to medicament | GUANGDONG HEC PHARMACEUTICAL | 2015-11-25 | — | — | CN | disclosed |
| US-20150246894-A1 | NOVEL OXAZOLIDINONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912034-A1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | F. Hoffmann-La Roche AG (CH) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014067861-A1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246894-A1 | NOVEL OXAZOLIDINONE COMPOUNDS | OXA1L, CDK11B, CDK11A | CES2 3210/4885CES1 3547/4885PSEN1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.